CTOs on the Move

Pediatric Home Services

www.pediatrichomeservice.com

 
We are dedicated to quality service for the medically fragile child. We service our patients based on each child's specific needs to develop their potential through clinical education and technical support. We believe it takes more than health care to
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Claudia Kuri
Chief Operating Officer Profile
Glenn Galloway
Executive VP Technology & Integrations Profile

Similar Companies

Jackson General Hospital

Jackson General Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Ripley, WV. To find more information about Jackson General Hospital, please visit www.jacksongeneral.com

Nursing Resources

Nursing Resources is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nautilus

Nautilus, Inc. is an iconic industry leader with a rich history and reputation as an innovative company building the best cardio and strength equipment for home use. Known for its family of brands that includes Bowflex®, Nautilus®, and Schwinn® Fitness, Nautilus, Inc. develops, manufacturers and markets branded products that include strength, cardio and fitness accessories through direct and retail channels. With its headquarters and innovation center located in Vancouver, Washington, Nautilus, Inc. employs nearly 500 employees and has offices in Brooklyn Park, Minnesota and Shanghai, China, as well as distribution centers in Portland, Oregon, Columbus, Ohio, and Rotterdam, The Netherlands.

PREtest Consult

PREtest Consult is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.